4/A: Revolution Medicines Director Barbara Weber Corrects Stock Ownership Reporting

Barbara Weber, a director at Revolution Medicines, files an amended Form 4 to correct previously reported amounts for restricted stock units and stock options granted on June 20, 2024.

Summary

• This is an amended SEC Form 4 filing by Barbara Weber, a director at Revolution Medicines, Inc.
• The amendment corrects inaccuracies in a previous Form 4 filed on June 24, 2024, regarding the amounts of restricted stock units (RSUs) and stock options granted to Weber on June 20, 2024.
• The corrected filing shows that Weber acquired 4,248 RSUs and an option to buy 15,955 shares of common stock at an exercise price of $37.54 on June 20, 2024.
• Following the reported transactions, Weber beneficially owns 20,073 shares of common stock, including the 4,248 RSUs, and options to purchase 15,955 shares.
• The stock options vest on the earlier of the first anniversary of the grant date (June 20, 2024) or immediately prior to the Issuer's annual meeting of stockholders following the date of grant, contingent upon continued service.

Sentiment

Score: 7

Explanation: The document is a routine correction of a regulatory filing. While not inherently positive or negative, accurate reporting is crucial for investor confidence, hence a neutral to slightly positive sentiment.

Future Outlook

The stock options vest on the earlier of the first anniversary of the grant date (June 20, 2024) or immediately prior to the Issuer's annual meeting of stockholders following the date of grant, contingent upon continued service.

Management Comments

• The remarks section indicates that the amended filing corrects errors in the original Form 4 regarding RSU and stock option awards.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, such as directors and officers. Correcting errors in these filings ensures transparency and compliance with SEC regulations.

Comparison to Industry Standards

• Stock option grants and RSU awards are common forms of compensation for directors and executives in publicly traded companies, particularly in the biotechnology and pharmaceutical industries.
• The vesting schedule of the stock options, contingent on continued service, aligns with standard practices to incentivize long-term commitment and performance.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize stock options and RSUs as part of their executive compensation packages.

Stakeholder Impact

• Accurate reporting of insider transactions ensures transparency for shareholders.
• Corrected filings maintain investor confidence in the company's governance and compliance.

Key Dates